Clinical trials for Breast cancer

243 currently recruiting clinical trials
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT05216432
Cohortes monothérapies (tumeurs solides PIK3CA mutées)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Relay Therapeutics, Inc.
Phase 1 Breast cancer #NCT06618287 #2024-514947-27-00
Cohortes C et D
Required HER2 statuses
HER2 Negative
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Bristol-Myers Squibb
Phase 1 Breast cancer #NCT06239467
Partie C
Required HER2 statuses
HER2 Positive
Required HR statuses
HR Negative HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded genetic anomalies
KRAS G12C KRAS G12D KRAS non G12C PTEN
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
OnKure, Inc.
Phase 1 Breast cancer #NCT06239467
Parties D et E
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
KRAS G12C KRAS G12D KRAS non G12C PTEN
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
OnKure, Inc.
Phase 1 Breast cancer #NCT06239467
Partie B
Required HER2 statuses
HER2 Negative HER2 Low
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy Antibody Drug Conjugates (ADC) Hormone therapy
Excluded genetic anomalies
KRAS G12C KRAS G12D KRAS non G12C PTEN
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
OnKure, Inc.
Phase 1 Breast cancer Colon cancer Rectal cancer #NCT06239467
Partie A
Required HER2 statuses
HER2 Negative HER2 Low HER2 Positive
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy Antibody Drug Conjugates (ADC) Hormone therapy
Excluded genetic anomalies
KRAS G12C KRAS non G12C KRAS G12D PTEN
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
OnKure, Inc.
Phase 1 Breast cancer Lung cancer Prostate cancer Anal cancer Kidney cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04064359
Cohortes A à D (Tumeurs solides CD205+)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Oxford BioTherapeutics Ltd